"I'm not very happy at all", – said the representative of Buddy Carter (R-Ga.), Whose bill limiting the ability of generics to block their competitors, was included in the package. "They know that we can not support it and that they put it there, I think it's just a bad policy."
House of Democrats defends maneuver as a budgetary necessity. The drug pricing trios would save about $ 4 billion over a decade, making them valuable reimbursements for Obamacare accounts, which require more federal spending to support health insurance markets and reciprocal reductions introduced by the administration.
POLITICO Pulse Newsletter
Get the latest news on the fight against medical aid, every weekday in the morning – into your inbox.
. But they limit the anticompetitive behavior of pharmaceutical companies and solve the question that shows the poll – it is a resonance with the voters of all political bands.
The Committee on Energy and Trade of Republicans, who unanimously supported the advancement of bills on the floor last month, unsuccessfully tried to persuade Democrat leaders to hold separate votes on drug pricing measures during a meeting with house rules and accused
"This should not be that way, "said Greg Walden (R-Ore.), a member of the rating committee. "But they are just waiting to cut TV ads."
Cruel feelings could penetrate other common health policy priorities such as protecting patients from medical accidents and a series of key health promotion extensions. 19659005] "For Republicans, they say we did it once, but we will have to trust you again," said Rodney Whitlock, a healthcare consultant and former assistant to the GOP Congress.
Incorporating the Obamacare clauses does everything but no doubt that the Senate will ignore the combined package, leaving pricing measures for drugs in a halt.
To reinstate these bills later this year and expand them in broader legislation, said one of the acquaintances, but this can be risky and delay the actions for half a year.
places himself in a stronger ne position in the Senate when they are doing a bipartisan job, "said Vitkov. "It actually says they will not."
Democratic leaders have come to the conclusion that the political benefits of developing a single package of medical services outweigh these risks, according to people familiar with this strategy, especially on issues that the party has made central. before the elections in 2020.
Democrats have already found several Republicans who want to refuse Trump's administration of health. The four moderate Republicans last week interrupted the ranks of legislation that abolished Trump's leadership, prompting states to evade the key protections of patients from Obamacare.
Democrats, however, are also concerned that the GOP is taking a bipartisan vote on drug prices, as proof of President Donald Trump's promise to cut costs for pharmaceutical products. It can cost democratic leverage in negotiating major priorities, such as allowing Medicare to negotiate directly with drug makers.
And tactics put the Senate in place, potentially making republican leaders seem to hinder progress in price pricing of drugs if they do not take a package of chambers.
"I would be very surprised if the AKA works out that [House and Senate] conference if the Democrats do not finally decide that they do not want to deal and live to fight one more day," said lobbyist of the drug industry
Michael Werner , who lobbied for some pharmaceutical bills. "We have about a year until we find ourselves in the full political season, and then all the bets are eliminated."
Democrats who voted for an autonomous vote on drug prices voiced doubts before voting on Thursday, arguing that it was important to state that an early bipartisan prize after the party held a nationwide campaign to reduce the cost of pharmaceuticals.
"Maybe I'm naive … I love people to be together," said fresh-freshman swing region Jeff Van Drew (D-N.J.), who said he would still support the package. "It's nice that we can go home and say that we have signed the signed law and now the law. That's one thing. It's just hard to make invoices. "
Chairman of the Energy and Commerce Subcommittee of the House, D-Calif, insisted on the division of drug prices and ACA bills along with a representative of Peter Welch, who has headed most of the work of the drug pricing committee. Representatives of David Cicilline (DR.I.) and Kurt Schrader (D-Ore.), Each of whom sponsored bills on drugs included in the package, were also among those who preferred a separate vote
. all is well. I think we will live to fight one more day, "Schroeder said. – Our management still explains how to play sandbox now, it's all new to them. So, I'll give them a bit of weakness, they do a good job. "
This article is tagged with:
Is missing the last scoop? Sign up for POLITICO Playbook and get the latest news every morning – in the Inbox.